Genotype variation of ACE and ACE2 genes affects the severity of COVID-19 patients.


Journal

BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768

Informations de publication

Date de publication:
04 Sep 2023
Historique:
received: 26 05 2023
accepted: 29 08 2023
medline: 6 9 2023
pubmed: 5 9 2023
entrez: 4 9 2023
Statut: epublish

Résumé

Genetic polymorphisms in ACE and ACE2 genes are involved in the RAS regulation of blood pressure and their activity may confer susceptibility to hypertension. In addition, they may play a role in SARS-CoV-2 pathogenesis and the severity of COVID-19. This study aims to determine the effect of genetic variations in the ACE (rs4331) and ACE2 (rs2074192) genes with hypertension comorbidity on the severity of COVID-19 in the Indonesian population. 186 patients were enrolled and assigned into the COVID-19 group (n = 95) and non-COVID-19 group (n = 91) in this cross-sectional study. GG genotype frequency was dominant in ACE gene, but there were no significant differences between the groups (p = 0.163). The two groups had a significant difference (p = 0.000) for the CC genotype frequency (0,37 vs. 0.01) in the ACE2 gene. The proportion of women with COVID-19 is higher (51%), but men with hypertension had more severe symptoms (44%). Men with hypertension comorbidity, GG (ACE), and TT (ACE2) genotypes tended to have moderate-to-severe symptoms (25%). Similarly, women with hypertension as well as GG and CT genotypes tended to have moderate-to-severe symptoms (21%). We conclude that hypertension and mutations in the ACE (rs4331) and ACE2 (rs2074192) genes affect the severity of COVID-19.

Identifiants

pubmed: 37667339
doi: 10.1186/s13104-023-06483-z
pii: 10.1186/s13104-023-06483-z
pmc: PMC10478384
doi:

Substances chimiques

Angiotensin-Converting Enzyme 2 EC 3.4.17.23
ACE2 protein, human EC 3.4.17.23
ACE protein, human EC 3.4.15.1
Peptidyl-Dipeptidase A EC 3.4.15.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

194

Subventions

Organisme : Universitas Indonesia via grant scheme Publikasi Terindeks Internasional Q2 (PUTI Q2) 2022-2023
ID : NKB-543/UN2.RST/HKP.05.00/2022
Organisme : Universitas Indonesia via grant scheme Publikasi Terindeks Internasional Q2 (PUTI Q2) 2022-2023
ID : NKB-543/UN2.RST/HKP.05.00/2022
Organisme : Universitas Indonesia via grant scheme Publikasi Terindeks Internasional Q2 (PUTI Q2) 2022-2023
ID : NKB-543/UN2.RST/HKP.05.00/2022
Organisme : Universitas Indonesia via grant scheme Publikasi Terindeks Internasional Q2 (PUTI Q2) 2022-2023
ID : NKB-543/UN2.RST/HKP.05.00/2022
Organisme : Universitas Indonesia via grant scheme Publikasi Terindeks Internasional Q2 (PUTI Q2) 2022-2023
ID : NKB-543/UN2.RST/HKP.05.00/2022
Organisme : Lembaga Pengelola Dana Pendidikan
ID : 20200411021593

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Hypertens Res. 2019 May;42(5):681-689
pubmed: 30542083
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
PLoS One. 2022 Feb 4;17(2):e0263140
pubmed: 35120165
PLoS One. 2013;8(4):e59537
pubmed: 23560051
Am J Hypertens. 2021 Apr 20;34(4):367-376
pubmed: 33386398
Front Immunol. 2022 Feb 17;13:812940
pubmed: 35250987
Virol J. 2022 Mar 19;19(1):48
pubmed: 35305693
PLoS One. 2013;8(3):e56119
pubmed: 23469169
Am J Hypertens. 2012 Feb;25(2):216-22
pubmed: 21993363
Int J Hypertens. 2020 Dec 4;2020:8019360
pubmed: 33489355
Crit Care. 2020 Jul 13;24(1):422
pubmed: 32660650
Ann Saudi Med. 2021 May-Jun;41(3):141-146
pubmed: 34085542
Genes (Basel). 2020 Sep 03;11(9):
pubmed: 32899439
Front Endocrinol (Lausanne). 2021 Aug 19;12:688071
pubmed: 34489863
Clin Chim Acta. 2021 Aug;519:206-209
pubmed: 33957095
Front Endocrinol (Lausanne). 2014 Jan 09;4:201
pubmed: 24409169
ERJ Open Res. 2021 Apr 19;7(2):
pubmed: 33889638
Wiley Interdiscip Rev RNA. 2013 Nov-Dec;4(6):677-91
pubmed: 23881603
DNA Cell Biol. 2020 Nov;39(11):2095-2101
pubmed: 33016778
Gene. 2020 Dec 15;762:145102
pubmed: 32882331
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184

Auteurs

Ingrid Faustine (I)

Faculty of Pharmacy, Universitas Indonesia, Depok, 16424, West Java, Indonesia.
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Tadulako University, Palu, 94148, Central Sulawesi, Indonesia.

Deli Marteka (D)

Faculty of Pharmacy, Universitas Indonesia, Depok, 16424, West Java, Indonesia.

Amarila Malik (A)

Division of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmacy, Universitas Indonesia, Depok, 16424, West Java, Indonesia. amarila.malik@ui.ac.id.

Eko Supriyanto (E)

Department of Biomedical Engineering & Health Science, Universiti Teknologi Malaysia, Johor Bahru, Johor, 81310, Malaysia.

Nadia F Syafhan (NF)

Division of Clinical Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, 16424, West Java, Indonesia.
Universitas Indonesia Hospital, Jl. Prof. Dr. Bahder Djohan, Pondok Cina, Depok, 16424, West Java, Indonesia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH